Despite encouraging clinical evidence, copyright's Vyndamax, a medication for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering significant difficulty from pharmacy benefit managers. These companies are often building limitations to coverage, such as steep price requirements and approval processes that hinder patient access. An